Detalhe da pesquisa
1.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Cell
; 172(4): 825-840.e18, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336888
2.
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Lancet Oncol
; 25(4): 488-500, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547893
3.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Invest New Drugs
; 38(5): 1448-1453, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125598
4.
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Biol Blood Marrow Transplant
; 24(8): 1581-1589, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29597002
5.
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Blood
; 124(3): 385-92, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859366
6.
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Haematologica
; 100(2): 223-30, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25381130
7.
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
Br J Haematol
; 166(6): 862-74, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24942980
8.
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist.
Clin Transl Sci
; 17(3): e13750, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451110
9.
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Invest New Drugs
; 30(4): 1597-606, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21629990
10.
Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Invest New Drugs
; 30(1): 316-26, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20839029
11.
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Invest New Drugs
; 29(1): 167-74, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19830388
12.
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Invest New Drugs
; 29(5): 1029-37, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20179989
13.
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Invest New Drugs
; 29(3): 481-8, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20016927
14.
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Lancet Oncol
; 11(1): 21-8, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19897418
15.
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
Invest New Drugs
; 28(3): 334-42, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19415181
16.
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clin Cancer Res
; 15(2): 723-30, 2009 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19147780
17.
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Clin Cancer Res
; 15(10): 3591-9, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19417019
18.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
N Engl J Med
; 354(6): 567-78, 2006 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-16467544
19.
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Clin Cancer Res
; 14(14): 4484-90, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18628463
20.
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Clin Cancer Res
; 14(23): 7884-95, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19047118